Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences, Inc. - Common Stock (NQ: SAVA )

3.020 +0.080 (+2.72%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
35 36 Next >
Why Cassava Sciences Stock Is Surging After Hours
Cassava Sciences Inc (NASDAQ: SAVA) shares are rising in extended trading Wednesday in the wake of recent insider buying.  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
3 Drug Stocks to Watch as Alzheimer’s Clinical Trials End
These drug companies are running clinical trials for Alzheimer's drugs. The cure is worth billions, so these are the drug stocks to watch. 
Via InvestorPlace
Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
3 Big Reasons to Sell Cassava Sciences Stock Right Now
It isn't about running out of money, but it's still laden with risk. 
Via The Motley Fool
If You Invested $100 In This Stock 5 Years Ago, You Would Have $400 Today
Via Benzinga
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a 
Via MarketBeat
Exposures Product Safety
Tesla, Amazon, Microsoft, Cassava Sciences, Intuitive Surgical: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed mixed on Tuesday as a disparate set of corporate earnings dampened the existing euphoria over the possibility of a slowdown in rate hikes. 
Via Benzinga
Why Is Cassava Sciences (SAVA) Stock Down 20% Today?
Here's why shares of Cassava Sciences and SAVA stock are on the decline today, amid a relatively calm day overall. 
Via InvestorPlace
Cassava Sciences Stock Is Diving: What's Going On?
Cassava Sciences Inc (NASDAQ: SAVA) shares are trading significantly lower Tuesday after the company announced top-line clinical results from a Phase 2 study 
Via Benzinga
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in... 
Via Benzinga
$100 Invested In Cassava Sciences 5 Years Ago Would Be Worth This Much Today
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Cassava Sciences Shares Fall As Alzheimer's Candidate Worsens Patients With Moderate Disease
Via Benzinga
Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors
Some patients improved while taking the company's twice-daily pill. 
Via Investor's Business Daily
3M, Magna International And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded mostly higher, with the Dow Jones gaining over 50 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Dow Drops 100 Points; Verizon Issues Weak Earnings Forecast
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.31% to 33,524.12 while the NASDAQ fell... 
Via Benzinga
Why Is Cassava Sciences (SAVA) Stock Up 10% Today?
Cassava Sciences has completed part of an important Alzheimer’s disease treatment trial. Here's why SAVA stock may rise even more soon. 
Via InvestorPlace
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Is a Short Squeeze Coming in Cassava Sciences (SAVA) Stock?
Today, a rally across most meme stocks has investors looking at Cassava Sciences and SAVA stock due to the short interest in this stock. 
Via InvestorPlace
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish
2023 can be the year of biotechs after two consecutive years of negative or barely positive returns. 
Via Talk Markets
SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday
Stocks of companies with Alzheimer's candidates, including Cassava Sciences, Inc. (NASDAQ: SAVA) and Eli Lilly And Company (NYSE: LLY), spiked on Friday after the FDA granted accelerated approval to 
Via Benzinga
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session
Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD
From Cassava Sciences, Inc.
Via GlobeNewswire
Is Anavex Life Sciences a Buy?
It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's. 
Via The Motley Fool
Tesla, Apple, GameStop, Prometheus Biosciences, Cassava Sciences: Why These 5 Stocks Are Drawing Investors' Attention Today
U.S. markets continued their weak trend on Wednesday, with next week’s Federal Open Market Committee meeting beginning to weigh on investors’ minds. 
Via Benzinga
Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Announces Closing of $50 Million Registered Direct Offering
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
From Cassava Sciences, Inc.
Via GlobeNewswire
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.